Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Polycystic Ovary Syndrome 3Fatty Liver 2Diabetes Mellitus 2Thyroid Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Obesity 1Neoplasms 1Menstruation Disturbances 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Iron Overload 1Hypertriglyceridemia 1Hyperthyroidism 1Hemoglobinopathies 1Graves Disease 1Glucose Metabolism Disorders 1Glucose Intolerance 1Fibrous Dysplasia, Polyostotic 1Fibrous Dysplasia of Bone 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Glucose Tolerance Test × Clear all
NCT03415139 2022-03-28

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

Vanderbilt-Ingram Cancer Center

Unknown
120 enrolled

Diabetes Mellitus, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡